STAT6 and myeloid sarcoma: These results, along with the therapeutic effect in STAT6-deficient mice and our inability to demonstrate Th2 polarization at the time of AT treatment, suggest that the cytostatic effect of statin treatment may provide the predominant mechanism responsible for observed benefits in MS clinical trials.